News and Comments

Human Longevity Firm Aims at Bringing the Missing Full Picture of Human Health

  Thursday, April 07, 2016

  More...

Gilead's Well Chosen New Acquisition Is Not the Last, It Is Just the Beginning

  Monday, April 04, 2016

Many in Wall Street have been anxious, sitting on fire while waiting to learn, which biotech company Gilead Sciences (GILD) would decide upon acquiring that would deepen and enhance its pipeline. In Today’s news, a firm called Nimbus Therapeutics, LLC today announced that it has signed a definitive agreement under which terms Gilead will acquire Nimbus Apollo, Inc., a Nimbus Therapeutics wholly-owned subsidiary. Important is that the acquisition includes the firm’s Acetyl-CoA Carboxylase (ACC) inhibitor program. The cost, which is around $1.2 billion will be given in an upfront payment of $400 million and an additional $800 million in development-related milestones over time. More...

Alder Biopharmaceutical Migraine Headache Drug Passes the Test. Our Voting Regarding Acadia Drug Nuplazid Approval

  Monday, March 28, 2016

Alder Reports Phase 2b Trial of ALD403 Meets Primary and Secondary Endpoints Demonstrating Migraine Prevention in Patients with Chronic Migraine More...

Vitae Pharmaceuticals: Opening a New Door Towards the Management of Psoriasis. The Drug Could Be Great for Many Other Autoimmune Diseases.

  Thursday, March 17, 2016

Published articles in peer review journals cited that pharmacologic inhibition of RORγt regulates Th17 signature gene expression and suppresses cutaneous inflammation in vivo. Here we are, a clinical stage small company called Vitae Pharmaceuticals (VTAE) has just announced positive results from its Phase 2a proof-of-concept clinical trial of its RORyt inhibitor drug VTP-43742 in psoriatic patients.  More...

GW Pharmaceuticals: A Cannabinoid Product Succeeds in Treating a Resistant Epilepsy. Stock Price Doubled.

  Monday, March 14, 2016

London, UK; 14 March 2016:  GW Pharmaceuticals (GWPH), is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform. The firm announced the positive results of the first pivotal Phase 3 study of its investigational medicine Epidiolex® (cannabidiol or CBD) for the treatment of Dravet syndrome. In this study, the firm’s product, Epidiolex, achieved the primary endpoint of a significant reduction in convulsive seizures assessed over the entire treatment period compared with placebo (p=0.01).  More...

One Year Accomplishments Vs. One Cent Missed in Agenus Financial Report

  Thursday, March 03, 2016

Agenus (AGEN) is a project in the making since the firm has decided to play an integral part in immuno-oncology, doing everything possible towards building checkpoint modulator antibodies, in addition to its protective and therapeutic vaccines.    More...

Exelixis: Great News Towards Great Changes

  Tuesday, March 01, 2016

Exelixis’ (EXEL) quarterly results beat analysts’ expectations, which was the least of our concerns. The details of the firm’s actions during the past year, however, confirmed our conviction that the recently approved products will be taken care of responsibly by the firm that created them and believed in them against all pessimistic opinions.  More...

AERIE Pharmaceuticals: The Novel Glaucoma Eye Drops Confirm Their Superiority

  Thursday, February 18, 2016

On February 4, 2015, under the title “Airie Pharmaceuticals is speeding towards improving the treatment of glaucoma”, we wrote the following under News & Comments in the Prohost Website: More...

Regulus Offers Proof of Concept and Feasibility with Its HCV RNA Targeted Drug

  Wednesday, February 17, 2016

Regulus Pharmaceuticals (RGLS) a biopharmaceutical company that discovers, designs and develop treatments targeting microRNAs announced interim results from one of the company's ongoing Phase 2 studies of its hepatitis C virus (HCV) product RG-101.   More...

Knowing Better About Gilead and Amgen. The Mess and Miss Following the Storm

  Friday, February 05, 2016

Gilead Sciences More...


Recent Postings


Archive


Tags

Revlimid (lenolidamide) Agenus (AGEN Editas (EDIT) Bristol-Myers Squibb (BMY) Dynavax (DVAX) Tysabri Ridaforolimus Merck (MRK) Inovio (INO) Vitae Pharmaceuticals (VTAE) Telaprevir Prolor Biotech (PBTH) Valeant Pharmaceuticals International (VRX) Agenus (AGEN) Exelixis (EXEL) REGULUS (RGLS) ACADIA (ACAD) Velcade (bortezomib) Alnylam (ALNY) Idenix (IDIX) Multiple Myeloma Prosensa (RNA) Galena (GALE) VANDA (VNDA) Sanofi (SNA) AstraZeneca (AZN) INNOVIVA (INVA) Jazz Pharmaceuticals (JAZZ) Intercept (ICPT) IDERA (IDRA) Amgen (AMGN) Incyte (INCY) Sanofi (SNY) Intermune (ITMN) GlaxoSmithKline (GSK) GUARDIAN HEALTH JUNO (JUNO) AERIE PHARMACEUTICALS Biogen Idec (BIIB) ADVENTRIX (ANX) Aimmune Therapeutics (AIMT) Rapamune Benlysta (belimumab) ISIS (ISIS) BIOMARIN (BMRN) SYNTA (SNTA) Pluristem (PSTI) HALOZYME (HALO) Endometrial Cancer Alder Biopharmaceuticals (ALDR) Elan (ELN) Sanofi-Aventis (SAN) Genentech Roche (ROCHE) Roche (RHHBY) KERYX (KERX) ImmunoGen (IMGN) Gilead (GILD) Anadys (ANDS) NANTKWEST (NK) Regeneron (REGN) Anacor (ANAC) Human Genome Sciences (HGSI) Human Longevity (HLI) Zerenex Seattle Genetics (SGEN) AGOS (ARGS) TOKAI (TKAOI) Herceptin ZALTRAP™ Theravance Bio Pharma (TBPH) Spike Therapeutics (ONCE) Trastuzumab-DM1 Theravance (THRX) OSI (OSIP) Dendreon (DNDN) NEKTAR (NKTR)) Array Pharmaceuticals (ARRY) SUNESIS PHARMACEUTICALS (SNSS) Micromet (MITI) Biocryst (BCRX) Sangamo (SGMO) Xoma (XOMA) ABBVIE (ABBV) CompuGen (CGEN) Illumina (ILMN) NOVOCURE (NVCR) Ionis (IONS) Sarepta (SRPT) KITE (KITE) SERES THERAPEUTICS (MCRB) Intrexon (XON) Ariad (ARIA) ARGOS (ARGS) galapagos (GLPG) Abbott Laboratories (ABT) Onyx (ONXX) C4 Therapeutics Sequenom (SQNM) Global Cell Therapeutics (GBT) Ziofpharm (ZIOP) Vertex (VRTX) PTC Therapeutics (PTCT) ARCA (ABIO) Mirati Therapeutics (MRTX) MODERNA RenenxBio (RGNX) Auspex (ASPX) Cytokinetics (CYTK)